Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate antibiotic treatments for acute pyelonephritis AP in children aged 1 month to 3 years. It compares a shorter intravenous IV antibiotic course of 3 days alone to a longer treatment consisting of 3 days IV followed by 7 days of oral antibiotics. The goal is to see if the shorter IV treatment is as effective in curing AP and preventing recurrence and renal scarring, while reducing the risk of antibiotic resistance and preserving gut microbiota diversity. Participants are randomly assigned to one of two groups. The experimental group receives only 3 days of IV antibiotics with ceftriaxone andor amikacin, after which treatment is stopped. The control group receives the usual care of 3 days IV antibiotics followed by 7 days of oral antibiotics, either cotrimoxazole or cefixime. The study includes collection of fecal or rectal swabs and blood tests to assess microbiota and resistance. Treatment effectiveness and safety are compared between groups. During the study, children are monitored for fever, symptoms, and urine cultures to confirm infection clearance. Researchers measure recurrence of febrile urinary tract infections within 28 days after treatment ends and follow clinical cure at 10 or 17 days depending on the group. Additional assessments include monitoring recurrence at 90 days, antimicrobial resistance in gut bacteria, and intestinal microbiota diversity over about a month. Participation lasts through treatment and follow-up visits up to several weeks.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
This research aims to evaluate the best way to manage fever in patients with septic shock who require mechanical ventilation and sedation. Septic shock is a severe condition with high mortality, often linked to infections like pneumonia. Fever can increase oxygen use and inflammation, potentially worsening organ failure, but may also slow bacterial and viral growth. Previous pilot studies showed that controlling fever with external cooling improved shock resolution and organ function, though effects on longer-term survival remain unclear. This trial compares two fever management strategies to see which better reduces mortality at 60 days. Participants will be randomly assigned to one of two groups one will receive fever control by external cooling to maintain normal body temperature for 48 hours, and the other will have their fever respected without antipyretic therapy. The study uses covariate-adaptive randomization and includes a subgroup with acute respiratory distress syndrome ARDS. An independent safety committee will monitor serious adverse events, and interim analyses may adjust enrollment based on results. Throughout the study, participants will be monitored for mortality at 60 days as the primary outcome. Secondary measures include organ function scores, days free from ventilators, kidney therapy, vasopressors, and monitoring for complications like shivering, seizures, hypothermia, arrhythmias, infections, ARDS development, and acute kidney injury. The trial spans several years, with detailed assessments during and after treatment to evaluate the impact of fever management strategies on patient outcomes.
Actively Recruiting
Obesity is a serious condition affecting 17% of the French population, with bariatric and metabolic surgery recognized as the primary treatment. This trial evaluates whether using the Da Vinci robot for bariatric surgery offers a cost-effective advantage over conventional laparoscopic surgery by potentially reducing complications and improving quality of life. The study is a randomized, controlled, single-blind, multicenter trial involving 482 patients undergoing primary or revisional bariatric surgery. Participants are randomly assigned to receive either robot-assisted bariatric surgery using the Da Vinci X or Xi system or conventional laparoscopic surgery. The study collects data on healthcare consumption linked to the surgeries by matching patient information with the French National Health Insurance database. Quality of life is assessed with the EQ-5D-5L questionnaire. Both surgical approaches follow the recommendations of the French National Authority for Health regarding eligibility based on body mass index and comorbidities. During the study, participants will undergo assessments of surgical complications, pain levels, readmission and reintervention rates, quality of life through questionnaires, duration of surgery, hospital stay, weight loss, and treatment changes up to 12 months after surgery. Data on costs and health outcomes will be analyzed to calculate the incremental cost-effectiveness ratio at one year. The total study duration extends to July 2028, with ongoing monitoring of health and economic outcomes relevant to bariatric surgery.
Actively Recruiting
Researchers are studying patients who have lived for three years or more after being diagnosed with metastatic lung cancer and who are no longer receiving cytotoxic chemotherapy. The study aims to understand these patients clinical characteristics, health status, socioeconomic impacts, quality of life, and their ability to return to work. This observational research focuses on both non-small cell lung cancer NSCLC and small cell lung cancer SCLC. Participants will be observed over time without receiving experimental treatments. They will complete several questionnaires related to quality of life, anxiety, and depression at the start of the study, then at 6 and 12 months, and annually for up to five years. Their health and treatment history, including any ongoing therapies like immunotherapy or targeted therapy, will be recorded throughout the study. During the study, participants will continue their usual medical care and attend regular consultations as needed. Researchers will collect data through questionnaires and health evaluations to measure clinical characteristics, health status, socioeconomic factors, and psychological well-being. The main outcomes include baseline clinical data and repeated assessments over five years to better understand long-term survivorship after metastatic lung cancer diagnosis.
Actively Recruiting
The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age. Participants will: * Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months